Researchers say early deep brain stimulation and emerging therapies could reshape expectations for patients diagnosed in the ...

An estimated 1.1 million Americans are living with Parkinson’s disease (PD), making it the second most common neurodegenerative disease after Alzheimer’s. “Parkinson’s is a disease in which neurons ...

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

Japan Approves Worlds First iPS Therapies for Parkinsons, Heart Failure Conditional approval granted for Sumitomo Pharmas ...

A pioneering clinical trial is exploring whether lab-engineered stem cells can restore dopamine production in people with Parkinson’s disease.

With the introduction of adaptive deep brain stimulation (aDBS) for Parkinson's disease, new questions emerge regarding who, why, and how to treat. This paper outlines the pathophysiological rationale ...

Throughout 2021 and 2022, researchers at Ghent University Hospital in Belgium watched with cautious optimism as nearly 50 people with early stage Parkinson’s disease visited the clinic as part of a ...

An experimental brain implant can capture the signals of movement-related brain regions while Parkinson’s patients perform daily activities like walking to the kitchen or strolling through a park, ...

Shares of Japan's Sumitomo Pharma fell over 12% on the back of profit-taking after a specialist panel endorsed its iPS ...